Comparing the public health burden of chronic hepatitis C and HIV infection in France

Journal of Hepatology

Volumn 40, Issue 2, 2004, Pages 319-326

  Deuffic Burban, Sylvie ^a   Wong, John B ^b   Valleron, Alain Jacques ^a   Costagliola, Dominique ^c   Delfraissy, Jean François ^d   Poynard, Thierry ^c  

^a INSERM   (France)

^b TUFTS MEDICAL CENTER   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

AIDS; Back calculation; Disease burden; HCV; Hepatocellular carcinoma; Liver disease; Mortality; Predictions

Indexed keywords

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; FRANCE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; POPULATION MODEL; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE;

EID: 1642491773     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2003.10.018     Document Type: Article

References (41)

1. Dubois F., Desenclos J.C., Mariotte N., Goudeau A., Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology. 25:1997;1490-1496.
2. Lot F., Pillonel J., Pinget R., Cazein F., Gouezel P., Laporte A. Diminution brutale du nombre de cas de SIDA. Rôle des nouvelles stratégies thérapeutiques? (French). Bull Épidémiol Hebdomadaire. 11:1997;43-50.
3. Raguin G., Rosenthal E., Cacoub P., Veyssier P., Piette J.C., Micoud M. Hepatitis C in France: a national survey in the departments of Internal Medicine and Infectious Diseases. Eur J Epidemiol. 14:1998;545-548.
4. Deuffic S., Buffat L., Poynard T., Valleron A.-J. Modeling the HCV epidemic in France. Hepatology. 29:1999;1596-1601.
5. Brookmeyer R., Gail M. The minimum size of the AIDS epidemic in the United States. Lancet. ii:1986;1320-1322.
6. Deuffic S., Costagliola D. Is the AIDS incubation time changing? A backcalculation approach. Stat Med. 18:1999;1031-1047.
7. Pagliaro L., Peri V., Linea C., Camma C., Giunta M., Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol. 31:1999;28-44.
8. Degos F., Christidis C., Ganne-Carrié N., Farmachidi J.-P., Degott C., Guettier C., et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 47:2000;131-136.
9. El-Serag H.B., Mason A.C., Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 33:2001;62-65.
10. Agence Nationale d'Accréditation et d'Evaluation en Santé. Traitement de l'hépatite C (French). In: Conférence de consensus 2002, Paris; 27-28 février 2002.
11. Manns M., McHutchinson J.G., Gordon S., Rustgi V., Shiffman M.L., Reindollar R., et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
12. Poynard T., Bedossa P., Opolon P., for the OBSVIRC, METAVIR, CLINIVIR, DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 349:1997;825-832.
13. Bréchot C., Jaffredo F., Lagorce D., Gerken G., zumBuschenfelde K.M., Papakonstontinou A., et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol. 29:1998;173-183.
14. Fong KW, Jefferson TH, Suyehiro T, Walton L. SLATEC Common Mathematical Library; 1993.
15. Marquardt D. An algorithm for least-squares estimation of nonlinear parameters. J Soc Ind Appl Math. 11:1963;431-441.
16. Tassie J.M., Grabar S., Lancar R., Deloumeaux J., Bentata M., Costagliola D. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. J Acquir Immune Defic Syndr. 30:2002;81-87.
17. Becker N.G., Marschner I.C. A method for estimating the age-specific relative risk on HIV infection from AIDS incidence data. Biometrika. 80:1993;165-178.
18. Marshner I.C. Using time of first positive HIV test and other auxiliary data in back-projection of AIDS incidence. Stat Med. 13:1994;1959-1974.
19. Rosenberg P.S. Backcalculation models of age-specific HIV incidence rates. Stat Med. 13:1994;1975-1990.
20. Muñoz A., Xu J. Models for the incubation of AIDS and variations according to age and period. Stat Med. 15:1996;2459-2473.
21. Veugelers P.J., Cornelisse P.G., Craib K.J., Marion S.A., Hogg R.S., Strathdee S.A., et al. Models of survival in HIV infection and their use in the quantification of treatment benefits. Am J Epidemiol. 148:1998;487-496.
22. Brookmeyer R., Liao J. The analysis of delays in disease reporting: methods and results for the acquired immunodeficiency syndrome. Am J Epidemiol. 132:1990;355-365.
23. Retel O., Costagliola D., Valleron A.-J. Analyse des délais de déclaration des cas de syndromes d'Immunodéficience Acquise en France (French). Rev Epidemiol Sante. 41:1993;447-453.
24. Bernillon P., Lièvre L., Pillonel J., Laporte A., Costagliola D. Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficience Humaine. Int J Epidemiol. 29:2000;168-174.
25. Efron B., Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Stat. 37:1983;36-48.
26. Wong J., McQuillan G.M., McHutchinson J.G., Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 90:2000;1562-1569.
27. Zou S., Tepper M., El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol. 14:2000;575-580.
28. Sagmeister M., Renner E.L., Mullhaupt B., Wong J.B. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol. 14:2002;25-34.
29. Griffiths J., Nix B. Modeling the hepatitis C virus epidemic in France using the temporal pattern of hepatocellular carcinoma deaths. Hepatology. 35:2002;709-715.
30. Ng I.O., Lai E.C., Fan S.T., Ng M.M., So M.K. Prognostic significance of pathologic features of hepatocellular carcinoma. Cancer. 76:1995;2443-2448.
31. Primary liver cancer in Japan. Ann Surg. 211:1990;277-287.
32. Freeman A.J., Dore G.J., Law M.G., Thorpe M., Von Overbeck J., Lloyd A.R., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 34:2001;809-816.
33. Survival after introduction of HAART in people with known duration of HIV-1 infection. Concerted action on seroconversion to AIDS and death in Europe (letter). Lancet. 355:2000;1158-1159.
34. Concerted action on seroconversion to AIDS and death in Europe. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: a collaborative reanalysis. Lancet. 355:2000;1131-1137.
35. Egger M., Junghans C., Friis-Moller N., Lundgren J.D. Highly active antiretroviral therapy and coronary heart disease: the need for perspective. AIDS. 15:2001;S193-S201.
36. Chaix M.L., Descamps D., Deveau C., Schneider V., Harzic M., Tamalet C., et al. Antiretroviral resistance, molecular epidemiology and response to initial therapy among patients with HIV-1 primary infection in 1999-2000 in France (Abstract). Antivir Ther. 7:2002;S138.
37. Masquelier B., Costagliola D., Schmuck A., Cottalorda J., Schneider V., Izopet J., et al. Prevalence of HIV-1 variants with multiple class drug resistance: a French nationwide study (Abstract). Antivir Ther. 7:2002;S136-S137.
38. Blower S.M., Aschenbach A.N., Gershengorn H.B., Kahn J.O. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med. 7:2001;1016-1020.
39. Soriano V., Sulkowski M., Bergin C., Hatzakis A., Cacoub P., Katlama C., et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 16:2002;813-828.
40. Mizokami M., Orito E., Tanaka E., Johnson J.Y.N., Suzuki Y., Shin-I T., et al. Divergence of hepatitis C virus in Japan versus United States estimated by molecular evolutionary analysis - implications on health impact (Abstract). Hepatology. 34:1999;421A.
41. El-Serag H.B., Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 160:2000;3227-3230.